

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

Assignment ID: PATI70126

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST
CONVEYING PARTY DATA	
Name	Execution Date
XERIS PHARMACEUTICALS, INC.	03/05/2024
STRONGBRIDGE DUBLIN LTD.	03/05/2024
RECEIVING PARTY DATA	
Company Name:	HAYFIN SERVICES LLP
Street Address:	One Eagle Place
City:	London
State/Country:	UNITED KINGDOM
Postal Code:	SW1Y 6AF
PROPERTY NUMBERS Total: 17	
Property Type	Number
Application Number:	18180002
Application Number:	18357666
Application Number:	18168438
Application Number:	18490218
Application Number:	18490224
Application Number:	17930857
Application Number:	16945598
Application Number:	15763050
Application Number:	17319371
Application Number:	16888028
Application Number:	18453937
Application Number:	17319781
Application Number:	17094544
Application Number:	17226640
Application Number:	17151405
Application Number:	17655632
Application Number:	13879501
CORRESPONDENCE DATA	

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 8004945225
Email: ipteam@cogencyglobal.com
Correspondent Name: Jay daSilva
Address Line 1: 1025 Connecticut Avenue NW
Address Line 2: Suite 712
Address Line 4: Washington, DISTRICT OF COLUMBIA 20036

ATTORNEY DOCKET NUMBER:	2292744 PAT
--------------------------------	-------------

NAME OF SUBMITTER:	Andrew Hackett
---------------------------	----------------

SIGNATURE:	Andrew Hackett
-------------------	----------------

DATE SIGNED:	03/05/2024
---------------------	------------

Total Attachments: 6

source=Xeris - Hayfin - Patent Security Agreement [Executed]#page1.tif
source=Xeris - Hayfin - Patent Security Agreement [Executed]#page2.tif
source=Xeris - Hayfin - Patent Security Agreement [Executed]#page3.tif
source=Xeris - Hayfin - Patent Security Agreement [Executed]#page4.tif
source=Xeris - Hayfin - Patent Security Agreement [Executed]#page5.tif
source=Xeris - Hayfin - Patent Security Agreement [Executed]#page6.tif

PATENT SECURITY AGREEMENT

This PATENT SECURITY AGREEMENT, dated as of March 5, 2024 (this “*Patent Security Agreement*”), made by each of the signatories hereto (together with any other entity that may become a party hereto as provided herein, the “*Patent Grantors*”), is in favor of Hayfin Services LLP, as administrative agent for the Secured Parties (in such capacity, together with its successors and assigns, the “*Agent*”).

W I T N E S S E T H:

WHEREAS, the Patent Grantors are party to a Security Agreement dated as of March 8, 2022 (as amended, amended and restated, supplemented, renewed, extended or otherwise modified from time to time, the “*Security Agreement*”) in favor of the Agent, pursuant to which the Patent Grantors are required to execute and deliver this Patent Security Agreement (capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Security Agreement);

WHEREAS, pursuant to the terms of the Security Agreement, each Patent Grantor has created in favor of the Agent a security interest in, and the Agent has become a secured creditor with respect to, the Patent Collateral (as defined below);

NOW, THEREFORE, in consideration of the premises and to induce the Agent and the Lender to enter into the Credit Agreement and to induce the Lender to make their respective extensions of credit to the Borrower thereunder, each Patent Grantor hereby grants to the Agent, for the ratable benefit of the Secured Parties, a security interest in all of the following property now owned or at any time hereafter acquired by such Patent Grantor or in which such Patent Grantor now has or at any time in the future may acquire any right, title or interest (collectively, the “*Patent Collateral*”), as collateral security for the complete payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of all Secured Obligations:

(a) all Patents of such Patent Grantor, including, without limitation, the registered and applied-for Patents of such Grantor listed on **Schedule 1** attached hereto;

(b) to the extent not covered by **clause (a)**, all Proceeds of any of the foregoing;
and

(c) to the extent not covered by **clause (a)**, all causes of action arising prior to or after the date hereof for infringement of any of the Patents.

The security interest granted pursuant to this Patent Security Agreement is granted in conjunction with the security interest granted to the Agent pursuant to the Security Agreement, and the Patent Grantors hereby acknowledge and affirm that the rights and remedies of the Agent with respect to the security interest in the Patents made and granted hereby are more fully set forth in the Security Agreement. In the event that any provision of this Patent Security Agreement is deemed to conflict with the Security Agreement, the provisions of the Security Agreement shall govern.

Each Patent Grantor hereby authorizes and requests that the Commissioner of Patents and Trademarks record this Patent Security Agreement.


THIS PATENT SECURITY AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES UNDER THIS PATENT SECURITY AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.

This Patent Security Agreement may be executed by one or more of the parties to this Patent Security Agreement on any number of separate counterparts, and all of said counterparts taken together shall be deemed to constitute one and the same instrument. Delivery of an executed signature page of this Patent Security Agreement by facsimile transmission or electronic transmission (in PDF format) shall be effective as delivery of a manually executed counterpart hereof.


[Signature Pages Follow]

IN WITNESS WHEREOF, each Patent Grantor has caused this Patent Security Agreement to be executed and delivered by its duly authorized officer as of the date first above written.

XERIS PHARMACEUTICALS, INC.

By:  DocuSigned by:
AB48F51F1087402...
Name: Steven M. Pieper
Title: Chief Financial Officer

STRONGBRIDGE DUBLIN LTD.


By:  DocuSigned by:
AB48F51F1087402...
Name: Steven M. Pieper
Title: Director

Xeris Biopharma Holdings, Inc.
1375 West Fulton Street, Suite 1300
Chicago, IL 60607
Attn: Legal Department
Email: legal@xerispharma.com

With a copy to:

Goodwin Procter LLP
The New York Times Building
620 Eighth Avenue
New York, NY 10018
Attn: Kevin Grumberg
Tel.: +1 212 459 7147
Email: KGrumberg@goodwinlaw.com

Accepted and Agreed:
HAYFIN SERVICES LLP

By 
Name: Nicola O'Regan
Title: Authorized Signatory

Address for Notices:
One Eagle Place
London, SW1Y 6AF
Email: Andrew.Merrill@hayfin.com
Michael.Tischler@hayfin.com
gc@hayfin.com
Tel: +44 207 074 2900
Attention: Nicola O'Regan, Andrew Merrill, Michael Tischler, Legal Team / Loan Operations

With a copy (which shall not constitute notice) to:

Morrison & Foerster LLP
250 West 55th Street
New York, NY 10019
Attn: Mark S. Wojciechowski
Tel.: (212) 468 - 8079
Email: MWojciechowski@mfo.com

PATENTS**I. Xeris Pharmaceuticals Patents/Applications**

Country	Application No.	Application Date	Patent No.	Grant Date	Title
United States of America	18/180,002	03/07/2023	(pending)	(pending)	METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTS
United States of America	18/357,666	07/24/2023	(pending)	(pending)	TREATMENT OF EXERCISE-INDUCED HYPOGLYCEMIA IN TYPE 1 AND INSULIN USING TYPE 2 DIABETES
United States of America	18/168,438	02/13/2023	(pending)	(pending)	STABLE THERAPEUTIC COMPOSITIONS IN APROTIC POLAR SOLVENTS AND METHODS OF MANUFACTURING THE SAME
United States of America	18/490,218	10/19/2023	(pending)	(pending)	STABLE LEVOTHYROXINE COMPOSITIONS IN APROTIC POLAR SOLVENTS
United States of America	18/490,224	10/19/2023	(pending)	(pending)	SUSTAINED RELEASE INJECTABLE THERAPEUTIC FORMULATIONS USING APROTIC POLAR SOLVENTS
United States of America	17/930,857	09/09/2022	(pending)	(pending)	INJECTABLE HIGH CONCENTRATION PHARMACEUTICAL FORMULATIONS AND METHODS OF MANUFACTURING AND USE THEREOF
United States of America	16/945,598	07/31/2020	11,446,310	09/20/2022	STABLE FORMULATIONS FOR PARENTERAL INJECTION OF SMALL MOLECULE DRUGS
United States of America	15/763,050	09/25/2016	11,590,205	02/28/2023	METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTS
United States of America	17/319,371	05/13/2021	11,833,157	12/05/2023	PRECIPITATION RESISTANT SMALL MOLECULE DRUG FORMULATIONS
United States of America	16/888,028	05/29/2020	11,576,951	02/14/2023	STABLE THERAPEUTIC COMPOSITIONS IN APROTIC POLAR SOLVENTS AND METHODS OF MANUFACTURING THE SAME

II. Strongbridge Dublin Ltd. Patents/Applications

Country	Application No.	Application Date	Patent No.	Grant Date	Title
United States of America	18/453,937	08/22/2023	(pending)	(pending)	METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE
United States of America	17/319,781	5/13/2021	11,278,547	03/22/2022	METHODS OF TREATING DISEASE WITH LEVOKETOCONAZOLE
United States of America	17/094,544	11/10/2020	11,478,471	10/25/2022	METHODS AND COMPOSITIONS FOR TREATING DIABETES, METABOLIC SYNDROME AND OTHER CONDITIONS

United States of America	17/226,640	10/11/2019	(pending)	(pending)	LEVOKETOCONAZOLE FOR TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA AND PRIMARY ALDOSTERONISM
United States of America	17/151,405	06/11/2020	(pending)	(pending)	COMPOSITIONS AND METHODS OF USE
United States of America	17655,632	03/21/2022	(pending)	(pending)	METHODS OF TREATING DISEASE WITH LEVOKETOCONAZOLE
United States of America	13/879,501	10/13/2011	9,265,842	02/23/2016	COMPOSITIONS AND METHODS FOR TREATING ENDOCRINE, GASTROINTESTINAL OR AUTOIMMUNE DISORDERS

ny-2696468

RECORDED: 03/05/2024

**PATENT
REEL: 066647 FRAME: 0602**